Monoallelic and Biallelic Mutations in MAB21L2 Cause a Spectrum of Major Eye Malformations  by Rainger, Joe et al.
REPORT
Monoallelic and Biallelic Mutations in MAB21L2
Cause a Spectrum of Major Eye Malformations
Joe Rainger,1,16 Davut Pehlivan,2,16 Stefan Johansson,4,15,16 Hemant Bengani,1,16 Luis Sanchez-Pulido,6
Kathleen A. Williamson,1 Mehmet Ture,14 Heather Barker,12 Karen Rosendahl,7 Ju¨rgen Spranger,8
Denise Horn,9 Alison Meynert,1 James A.B. Floyd,5 Trine Prescott,10 Carl A. Anderson,5
Jacqueline K. Rainger,1 Ender Karaca,2 Claudia Gonzaga-Jauregui,2 Shalini Jhangiani,3
Donna M. Muzny,3 Anne Seawright,1 Dinesh C. Soares,13 Mira Kharbanda,11 Victoria Murday,11
Andrew Finch,12 UK10K, Baylor-Hopkins Center for Mendelian Genomics, Richard A. Gibbs,2,3
Veronica van Heyningen,1 Martin S. Taylor,1 Tahsin Yakut,14 Per M. Knappskog,4,15 Matthew E. Hurles,5
Chris P. Ponting,6 James R. Lupski,2,3,17 Gunnar Houge,4,17 and David R. FitzPatrick1,17,*
We identified four different missense mutations in the single-exon geneMAB21L2 in eight individuals with bilateral eye malformations
from five unrelated families via three independent exome sequencing projects. Three mutational events altered the same amino acid
(Arg51), and two were identical de novo mutations (c.151C>T [p.Arg51Cys]) in unrelated children with bilateral anophthalmia, intel-
lectual disability, and rhizomelic skeletal dysplasia. c.152G>A (p.Arg51His) segregated with autosomal-dominant bilateral coloboma-
tous microphthalmia in a large multiplex family. The fourth heterozygous mutation (c.145G>A [p.Glu49Lys]) affected an amino acid
within two residues of Arg51 in an adult male with bilateral colobomata. In a fifth family, a homozygous mutation (c.740G>A
[p.Arg247Gln]) altering a different region of the protein was identified in two male siblings with bilateral retinal colobomata. In mouse
embryos,Mab21l2 showed strong expression in the developing eye, pharyngeal arches, and limb bud. As predicted by structural homol-
ogy, wild-type MAB21L2 bound single-stranded RNA, whereas this activity was lost in all altered forms of the protein. MAB21L2 had no
detectable nucleotidyltransferase activity in vitro, and its function remains unknown. Induced expression of wild-type MAB21L2 in
human embryonic kidney 293 cells increased phospho-ERK (pERK1/2) signaling. Compared to the wild-type and p.Arg247Gln proteins,
the proteins with the Glu49 and Arg51 variants had increased stability. Abnormal persistence of pERK1/2 signaling in MAB21L2-
expressing cells during development is a plausible pathogenic mechanism for the heterozygous mutations. The phenotype associated
with the homozygous mutation might be a consequence of complete loss of MAB21L2 RNA binding, although the cellular function
of this interaction remains unknown.Structural eye malformations are an important cause of
congenital visual impairment.1,2 The terms anophthalmia
and microphthalmia are used to indicate the absence or
marked reduction in size, respectively, of an eye. Ocular
coloboma (MIM 216820) describes the spectrum of eye
malformations, including microphthalmia, resulting
from failure of optic fissure closure during embryogenesis.
These malformations show marked phenotypic and etio-
logical heterogeneity. The most common identifiable ge-
netic causes of structural eye malformations are those
involving dosage-sensitive transcription factors (encoded
by SOX2 [MIM 184429],3,4 OTX2 [MIM 600037],5 and
PAX6 [MIM 607108]6) and retinoic acid metabolism or
transport (regulated by STRA6 [MIM 610745],7 ALDH1A3
[MIM 600463],8 RARB [MIM 180220]9). The cause in a sig-1Medical Research Council Human Genetics Unit, Medical Research Council
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The Amnificant proportion of individuals with major eye malfor-
mations, particularly in those with microphthalmia and
coloboma,10,11 remains unknown.
To further elucidate the genetic architecture of ocular
coloboma, we performed exome sequencing on genomic
DNA from an affected uncle and nephew (individuals II.6
and III.1) in a large family (family 1463) in which appar-
ently isolated bilateral coloboma segregates in a pattern
consistentwith autosomal-dominant inheritance (Figure 1;
Figure S3 and Table S2, available online). These were two of
the 99 exome sequences (75 individuals with coloboma
and 24 unaffected relatives from 58 different families)
that comprised the coloboma contribution to the rare-
diseases component of the UK10K project.12 This study
was approved by the UK Multiregional Ethics CommitteeInstitute of Genetics and Molecular Medicine, Edinburgh EH4 2XU, UK;
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Figure 1. Family Structures and MAB21L2 Mutations
(A–E) Diagrammatic representation of the structure of the five families—1463 (A), 676 (B), 131 (C), 4480 (D), and 4468 (E)—in whom
mutations were identified in MAB21L2. The family number is given above each pedigree, and the sequencing chromatograms of the
mutated base are given below each pedigree. Clinical images associated with each of the probands are located on the right-hand side
of each cognate pedigree.
(F) The location of each missense mutation is provided on a schematic representation of MAB21L2.
916 The American Journal of Human Genetics 94, 915–923, June 5, 2014
(reference 06/MRE00/76), and informed consent was ob-
tained from all participating families. Exome sequencing
was performed as previously described.13 Sequences were
aligned with the Burrows-Wheeler Aligner v.0.5.9, dupli-
cates were marked with Picard v.1.43, realignment around
indels and base quality scores were recalibrated with the
Genome Analysis Toolkit (GATK) v.1.0.5506, and variants
were called only with GATK Unified Genotyper. The
coverage and depth metrics for these exomes and for
each of the other exome analyses mentioned below are
provided in Table S4. A total of 27 shared heterozygous,
rare (maximum allele frequency < 0.005 and mutation
count in UK10K coloboma exomes< 3) variants were iden-
tified (Table S1). Two frameshift and one in-frame deletion
were called in IFT122 (MIM 606045) but were the result of
misalignment of a single IFT122 heterozygous frameshift
mutation causing autosomal-recessive cranioectodermal
dysplasia (MIM 218330). All the remaining missense
mutations or in-frame deletions affected different genes.
Only one mutation (c.152G>A [p.Arg51His]; chr4:
g.151504333G>A) was found to alter a gene (MAB21L2
[MIM 604357]) on our previously compiled list of 38 candi-
date genes for eye malformations (Table S3). This mutation
is not reported in public databases, including the 1000
Genomes Project, the NHLBI Exome Sequencing Project
(ESP) Exome Variant Server, and the Medical Research
Council Human Genetics Unit in-house database of vari-
ants derived from ~2,200 exomes. The RefSeq accession
numbers NM_006439.4 and NP_006430.1 were used for
naming this and all subsequent MAB21L2 variants at
cDNA and protein levels, respectively. The entire UK10K
coloboma exome data set is available from the European
Genome-phenome Archive under a data-access agreement
as study number EGAS00001000127.
Independently, trio whole-exome sequencing of an
affected Norwegian female (II.1 in family 676 [Figure 1])
with bilateral anophthalmia, macrocephaly, moderate
intellectual disability, and generalized skeletal dysplasia
(Table S2) and her parents was performed as previously
described14 as part of a study approved by the Regional
Committee for Medical and Health Research Ethics in
western Norway (institutional review board [IRB]
00001872; written informed consent was obtained from
the family). A total of 217 rare variants (with a maximum
allele frequency< 0.005 in 1000 Genomes and not present
in 80 in-house-generated Norwegian exome samples from
the same pipeline) were detected in the proband and
filtered against parental exome data in a search for putative
de novo variants. Using this approach, we detected four
variants, of which only one (c.151C>T [p.Arg51Cys];
chr4: g.151504332C>T; in MAB21L2) was confirmed by
Sanger sequencing. This de novo missense mutation was
found to alter the same amino acid (Arg51) as that in
family 1463. The substitution changes a strictly conserved
residue, and both p.Arg51Cys and p.Arg51His are pre-
dicted to be deleterious by SIFT, PolyPhen2, and
AlignGVGD. Subsequently, one of the authors identifiedThe Aman unrelated male individual (II.1 in family 4480) with
more severe rhizomelic skeletal dysplasia associated with
bilateral anophthalmia (Figure 1; Table S2). Analysis of
DNA samples from this individual and his parents was per-
formed as part of the study approved by the UK Multire-
gional Ethics Committee (reference 06/MRE00/76;
informed consent was obtained from the family). Exactly
the same mutation (c.151C>T [p.Arg51Cys]), which had
also occurred de novo, was identified in the affected child.
Microsatellite analysis of the DNA samples from each
family was performed to confirm biological relationships
and to exclude sample mix up. The de novo mutation
c.151C>T (p.Arg51Cys) thus has a clinically recognizable
phenotype.
Resequencing of MAB21L2 was performed in 336 unre-
lated individuals with major eye malformations (and
with no overlap with those who were exome sequenced)
as part of the study approved by the UK Multiregional
Ethics Committee (reference 06/MRE00/76; informed con-
sent was obtained from all participating families). This
analysis revealed one different ultra-rare (not present in
the NHLBI ESP Exome Variant Server, 1000 Genomes, or
UK10K variant databases) heterozygous missense muta-
tion (Figure 1) in the simplex case of an adult male with
bilateral colobomatous microphthalmia (individual II.1
in family 131 [Figure 1; Table S2]). This mutation
(c.145G>A [p.Glu49Lys]; chr4: g.151504326G>A) affects
the codon encoding a residue two amino acids N-terminal
to the substitutions identified above (p.Arg51His and
p.Arg51Cys). This man had a history of reasonably good
vision until the age of 11 years, after which he became
blind over a period of 2 years. He had no evidence of retinal
detachment at the age of 30 years, and no retinal electro-
physiology was available. He was of normal intelligence
and had only minor skeletal dysmorphisms, recurrent
dislocation of the patellae, and soft-tissue syndactyly of
the third and fourth digits of his hands and of the second
and third digits of both feet (Table S2). His mother was
deceased, and therefore we were unable to confirm
whether this mutation had occurred de novo in this man.
A third independent exome sequencing study of distinct
clinical phenotypes in children of consanguineous parents
was carried out at the Baylor-Johns Hopkins Center for
Mendelian Genomics under ethical approval from the
Baylor College of Medicine (BCM) IRB (informed consent
was obtained from all participating families). Two male
siblings born to first-degree cousins were referred for clin-
ical genetic assessment as a result of eye abnormalities.
With the exception of subtle facial dysmorphic features
and the eye findings, both boys had normal development.
The elder boy (II.1 in family 4468) had left-eye esotropia in
addition to a prominent forehead, periorbital fullness, long
eyelashes, epicanthus, and a long and prominent philtrum
(Table S2). Ophthalmologic examination revealed retinal
coloboma including the optic disc and macula in the right
eye, whereas there was sparing of the optic disc andmacula
in the left eye. Refractions were þ2.0/þ3.0 3 170erican Journal of Human Genetics 94, 915–923, June 5, 2014 917
Figure 2. Mab21l2 Expression during Mouse Eye Development
OPT images of Mab21l2 expression at mouse Theiller stage 17
(TS17; 10.5 dpc). Hatched lines indicate the digital sections pre-
sented.
(A) Lateral 3D OPT projection showingMab21l2 expression in the
eye (E), pharyngeal arches (PAs), and forelimbs (FLs). The trans-
verse digital section presented alongside shows specific expression
in the eyes, and an enlarged image (box) illustrates Mab21l2
expression at the distal regions of the neural retina (NR), but not
in the lens vesicle (LV).
(B) Posterior 3D OPT view illustrating specificMab21l2 expression
in the FLs. The sagittal digital section presented alongside and the
enlarged box illustrate that Mab21l2 expression was highest
dorsally but continued ventrally into the margins of the optic
fissure (OF).
Further abbreviations are as follows: HB, hindbrain; and TV,
telencephalic vesicle.and 5.25/3.25 3 115 in the right and left eyes, respec-
tively. His younger brother (II.2 in family 4468) had
right-eye exotropia and microphthalmia in addition to
similar facial dysmorphic features. Ophthalmologic exam-
ination revealed bilateral retinal coloboma involving the
optic disc in the right, but not the left, eye. Refractions
were 2.00/2.00 3 90 and þ0.25/1.50 3 175 in the
right and left eyes, respectively. The parents of these
siblings had normal vision and had no evidence of an
asymptomatic structural eye malformation on ophthalmo-
logical examination.
Whole-exome sequencing in both affected siblings
identified a homozygous nonsynonymous substitution
(c.740G>A [p.Arg247Gln]; chr4: g.151504921G>A, hg19;
RefSeq NM_006439) in MAB21L2 in both brothers. This
mutation has not been reported in public databases,
including the 1000 Genomes Project, the NHLBI ESP
ExomeVariant Server, and the Atherosclerosis Risk in Com-
munities Study database. In addition, this p.Arg247Gln
substitution was not identified in an in-house-generated
exome variant database from ~2,500 individuals at the918 The American Journal of Human Genetics 94, 915–923, June 5, 2BCM Human Genome Sequencing Center and BCM
Whole Genome Laboratory Database, which includes ano-
nymized data from over 1,000 individuals tested for diag-
nostic purposes. Sanger sequencing was performed for
segregation analysis, and the parents were found to be
heterozygous carriers, consistent with Mendelian expecta-
tion. All experiments and analyses were performed accord-
ing to previously described methods.15
The human gene is named after the ortholog in
C. elegans. Mutations inMab-21 cause posterior-to-anterior
homeotic transformation of sensory ray 6 in the male
tail in this worm.16 In normal development, Mab-21 has
been shown to interact with Sin-3, a key component of a
histone-deacetylase-containing transcriptional regulatory
complex,17 and to be negatively regulated by CET-1 (whose
human paralogs are BMP2, BMP4, and BMP7) signaling.
After the identification of Mab-21 in C. elegans, multiple
orthologous proteins were identified in human18 and
mouse.19 In zebrafish, expression of mab21l2 in the
eye field is rx3 dependent. Morpholino knockdown of
mab21l2 has been shown to produce a proliferation defect
within the retinal progenitor cell population, resulting in
small but structurally normal eyes.20 Analysis of the cis-
regulatory elements surrounding mab21l2 has identified
functionally significant subpopulations of cells within
the developing eye,21 although the role of the gene
product in the formation or maintenance of these cells
is not yet clear. Homozygous targeted inactivation of
Mab21l2 in mouse embryos causes defects of the ventral
body wall, severe eye malformations, and death in midges-
tation, whereas heterozygous null animals are apparently
normal.22 Homozygous null embryos show failure of lens
induction and aplasia of the retinal pigment epithelium
as a result of a proliferation defect within the optic vesicle.
Given the severity of the phenotype observed in the
Mab21l2-null mouse embryos and the relatively mild
phenotype in the siblings homozygous for c.740G>A
(p.Arg247Gln), it seems likely that the human mutation
does not result in complete loss of function.
Although developmental expression of Mab21l2 in
mouse embryos has been previously reported,23 we wished
to examine the expression in the developing eye in more
detail. A digoxigenin-labeled antisense riboprobe targeted
to the 50 UTR of Mab21l2 (chr3: 86,547,729–86,548,237,
mm10) was used for whole-mount in situ hybridization
of 9.5, 10.5, 11.5, and 12.5 day postcoitum (dpc) mouse
embryos (Figure S3). In addition to bright-field imaging, op-
tical projection tomography (OPT) was also used for visual-
izing 10.5 dpc embryos as previously described.12We chose
10.5 dpc for full descriptive analysis because this time point
is prior to optic fissure closure but has a well-formed optic
cup. Strong expression was evident in the rostral and
distal regions of the developing neural retina (Figure 2A),
and there was no expression immediately adjacent to
the closing optic fissure (Figure 2B). Expression was also
observed in the dorsal and ventral aspects of the developing
forelimb bud and in the developing pharyngeal arches. The014
Figure 3. Structural Modeling of MAB21L2 and Prediction of Nucleotidyltransferase Activity
(A) Amodel ofMAB21L2was generatedwith PDB 4K9B as a template and is shown in purple; the nucleotidemonophosphates are shown
in green, blue, and red. This analysis suggests that MAB21L2 has both a nucleotidyltransferase active site and a DNA- and/or RNA-bind-
ing domain (double-stranded DNA is shown in pink in the foreground). The position of the residues that were altered in the affected
individuals is shown in white text in black boxes. The arginine residues (Arg51 [R51] and Arg247 [R247]) are highlighted in blue,
and the glutamic acid residue (Glu49 [E49]) is shown in orange.
(B) A graph showing the absence of OAS-like activity in purifiedMAB21L2.WhenOAS protein purified in the sameway asMAB21L2 was
incubated with ATP and double-stranded RNA (dsRNA), significant pyrophosphate release was detected, indicating nucleotidyltransfer-
ase activity. MAB21L2 showed no activity above background with ATP (or other nucleoside triphosphates [Figure S2]) using dsRNA,
double-stranded DNA, ssRNA, or ssDNA as an activator.
(C) An electromobility shift assay (EMSA) using fluorescently labeled I:C oligonucleotides shows binding of wild-type MAB21L2 to
ssRNA, but not ssDNA. The ssRNA binding could be completed efficiently with unlabeled ssRNA, but not ssDNA.
(D) Solution-based assay showing that wild-type MAB21L2 could efficiently bind a digoxigenin-labeled ssRNA molecule (this was an
antisense riboprobe against FZD5, but all probes tested behaved in an identical fashion). None of the altered proteins could bind the
ssRNA probe at levels above background.
The error bars in (B) and (D) represent SE. Each experiment represents readings from two biological replicates, and all experiments were
repeated twice.site- and stage-specific developmental expressionpattern of
Mab21l2 is thus compatible with the eye and limb pheno-
typic effects associated with the mutations we identified
above. No Mab21l2 expression was observed in the brain
at 10.5 dpc on OPT. However, imaging of more intensely
stained embryos showed striking midbrain expression of
Mab21l2 at 9.5 and 10.5 dpc (Figure S3). This might be
important in view of the neurodevelopmental problems
reported in the individuals (676 II.1 and 4480 II.1) carrying
the substitution p.Arg51Cys.
The highly localized distribution of the heterozygous
missense mutations suggests a mutational mechanism
that might not be simple loss of function. The biochemical
function of MAB21L2 is not known, but the residues at
which each of the amino acid substitutions occurredThe Am(Glu49, Arg51, and Arg247) in the human protein are
completely conserved in mouse, zebrafish, and C. elegans
(Figure S1). The family of 12 human Mab-21 paralogs
adopt a nucleotidyltransferase fold24 and include a cyclic
GMP-AMP synthase (cGAS), which generates cyclic GMP-
AMP in the cytoplasm of cells exposed to DNA.25 Detailed
examination of the structure of both cGAS (Protein Data
Bank [PDB] accession number 4K9B) and another family
member, RNA-activated antiviral protein 20-50-oligoadeny-
late synthetase (OAS26 [PDB 1PX5]), indicated conserva-
tion of the active site in MAB21L2 (Figure 3A). However,
a sensitive colorimetric assay using purified MAB21L2
(from E. coli or human embryonic kidney 293 [HEK293]
cells) with ATP as a substrate (Figure 3B) for analysis of py-
rophosphate release27 detected no nucleotidyltransferaseerican Journal of Human Genetics 94, 915–923, June 5, 2014 919
Figure 4. Protein Stability Estimations
and Induction of ERK Signaling by
MAB21L2
(A) Time-course analysis of protein stabil-
ity with the use of anti-GFP immunoblot-
ting of MAB21L2 at various time points
since tetracycline (Tet) removal. Data pre-
sented are representative of five indepen-
dent replicates.
(B) Quantification of immunoblots indi-
cates higher protein stability for the
proteins with substitutions at Glu49
or Arg51 than for the WT, whereas
p.Arg247Gln displayed a pattern of pro-
tein stability similar to that of the WT.
Error bars represent 95% confidence
intervals.
(C) Increase in the level of the 44 kDa
phospho-ERK band after 5 hr of Tet induc-
tion of WT and p.Arg51His MAB21L2 in
inducible HEK293 cells.
(D) Graph representing quantification of
this induction. Error bars represent 95%
confidence intervals.activity, whereas OAS purified by the same methods
resulted in strong activity. This analysis was repeated
with a mixture of all nucleoside triphosphates (Figure S2)
with different plausible activator molecules (double-
stranded RNA or DNA and single-stranded RNA [ssRNA]
or DNA [ssDNA]), but no enzymatic activity was detectable
for MAB21L2.
Enzymatic activation of OAS and cGAS occurs via
conformational changes induced by binding with RNA
and DNA, respectively.28 The structural comparisons sug-
gested that a ~35 A˚ long RNA- or DNA-binding groove
also exists inMAB21L2 (Figure 3A; Figure S1). A fluorescent
electromobility shift assay using Cy5- or Cy3-labeled
ssRNA and ssDNA oligonucleotides and bacterially ex-
pressed protein showed binding of MAB21L2 to ssRNA,
but not ssDNA (Figure 3C). To investigate the effect on
ssRNA binding in each of themutants (Figure 3D), we incu-
bated a digoxigenin-labeled ssRNA (500 nt in length) in
solution with sepharose-bead-bound wild-type or altered
protein. After extensive washing, the binding of ssRNA to
MAB21L2 was determined by fluorometry with an anti-
digoxigenin-fluorescein antibody (Roche). Each of the
four mutations, including the recessive mutation, resulted
in loss of ssRNA-binding activity, consistent with the pre-
dicted locations of the affected residues close to the OAS
RNA-binding cleft (Figure 3A). Complete loss of RNA bind-
ing in association with each of the mutations was remark-
able but clearly cannot explain why the c.740G>A
(p.Arg247Gln) variant is recessive and the other variants
are dominant.We also had no knowledge of what the func-
tional consequence of RNA binding was in the wild-type
protein.
We therefore created multiple independent stable tetra-
cycline-inducible HEK293 cell lines expressing the wild-
type MAB21L2 and each of the altered forms as full-length920 The American Journal of Human Genetics 94, 915–923, June 5, 2GFP-fusion proteins. We used this system first to accurately
determine the stability of the induced proteins by using a
timed pulse of tetracycline. These analyses showed that
all three of the monoallelic mutations resulted in signifi-
cant stabilization of the protein in comparison to either
the wild-type protein or the p.Arg247Gln variant (Figures
4A and 4B). Similar stabilization of altered protein has
been reported in the recurrent de novo PACS1 mutations,
associated with characteristic facial dysmorphisms and
significant intellectual disability.29 In this study, they
observed cytoplasmic aggregates of altered GFP-tagged pro-
tein, but we could identify no obvious aggregation or local-
ization differences in the MAB21L2 variants (Figure S4).
No predicted ubiquitination site could be located in the
vicinity of the MAB21L2 substitutions. However, failure
of the altered proteins to be recognized by the ubiquitin-
mediated degradation system is the most likely mecha-
nism for this observation.30
Given the above-mentioned data from C. elegans, we
used the inducible cell system to identify any MAB21L2-
dependent alteration in SMAD family member 1, 5, and
8 (SMAD1/5/8) signaling or extracellular-signal-regulated
kinase 1 and 2 (ERK1/2) signaling. Immunoblots using
anti-phospho-SMAD1/5/8 antibodies detected no alter-
ation in canonical BMP signaling between cells expressing
taggedMAB21L2 and the same cells cultured without tetra-
cycline (data not shown). However, induction of wild-type
MAB21L2 consistently resulted in an ~1.5-fold increase in
44 kDa phospho-ERK1 detected on immunoblot (Figures
4C and 4D). A similar level of induction was noted with
the p.Arg51His substitution (Figures 4C and 4D). In mouse
models of Noonan syndrome, an activating mutation
in Ptpn11 has been expressed as a transgene with the
use of different tissue-specific promoters. Expression in
the developing heart31 and craniofacial region32 produced014
ERK upregulation associated with specific developmental
defects. These malformations disappeared if the transgene
was expressed in an ERK1/2-null background31 or when
ERK1/2 signaling was chemically ablated.32 The pattern
of malformations associated with ERK-activating muta-
tions thus probably reflects the developmental expression
of the mutated gene. ERK1/2-mediated signaling is active
during eye and skeletal development and is almost entirely
dependent on FGF receptor in the early mouse embryo.33
The combination of protein stabilization and phospho-
ERK (pERK1/2) induction suggests that the mutational
mechanism in the monoallelic mutations affecting
MAB21L2 might be activating mutations. Overactive
pERK1/2 signaling is generally considered oncogenic, but
a paradoxical growth inhibitory effect in chondrocytes
has been recently proposed to explain how activating mu-
tations in FGFR3 (MIM 134934) can cause achondroplasia
(MIM 100800) and thanatophoric dysplasia (MIM
187600).34 In this model, pERK1/2 overactivity induces
cellular defense mechanisms, which are potent inhibitors
of growth. Such amechanism could explain the rhizomelic
skeletal dysplasia that is seen to be associated with
MAB21L2 mutations. However, given that the wild-type
protein and the p.Arg51His substitution result in similar
levels of ERK1/2 induction (1.5-fold; Figure 4), the impor-
tant aspect might be the inability to control the precise
timing of the pathway activity during critical develop-
mental processes rather than the absolute level of
signaling. The timing of ERK1/2 signaling is known to be
crucial for the oscillatory expression of cyclic genes during
somitogenesis,35 but it is not yet clear which processes
during ocular and skeletal development, if any, are timing
critical. ERK1/2 signaling has not been examined in
either mouse or zebrafish models for Mab21l2 or mab21l2
loss of function, respectively. However, ‘‘knocking in’’
these monoallelic mutations will be the most effective
method of answering the precise relationship among
these variants, ERK1/2 signaling, and the developmental
pathology.
This report provides compelling human genomic and
genetic evidence that mutations in MAB21L2 cause major
eye malformations. The combination of dominant and
recessive mutations is intriguing, particularly given that
the carriers of homozygous mutations are the least severely
affected. The restricted repertoire of mutations in the
monoallelic cases strongly suggests an unusual genetic
mechanism. A similar restricted pattern is seen in disorders
caused by the activation of signaling pathways, such as
RASopathy disorders36 and Myhre syndrome (MIM
139210).37 It is possible that the monoallelic mutations
act as dominant negative. The association between the
monoallelic mutations and increased protein stability
and the association between MAB21L2 and the induction
of pERK signaling raise the possibility that aberrant persis-
tence of a developmental signal might be the mechanism
operating in those cases. It could be that complete loss
of MAB21L2 RNA-binding activity in association withThe Amthe recessive Arg247Gln variant might be producing
the eye phenotype via a different mechanism, and as
such, identifying the in vivo role of the RNA-binding activ-
ity is a priority for future work. An understanding of
the cellular and developmental function of wild-type
MAB21L2 will enable adequate interpretation of muta-
tions at this locus in a clinical setting. Finally, this study
illustrates the cumulative value of the active sharing
of DNA variation observed in individual patients in
order to aggregate sufficient evidence to support specific
biological hypotheses.Supplemental Data
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